Analyzing the options chain of IOVA Iovance Biotherapeutics prior to the earnings report this week,
I would consider purchasing the 7.5usd strike price Puts with
an expiration date of 2023-6-16,
for a premium of approximately $0.70
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read...
IOVA formed a large bearish Rising Wedge on this Weekly timeframe
This has led to a big downward move, which correlates well with the rising wedge, being a primarily bearish pattern
Support has yet to be found on the Weekly timeframe
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary...
